Welcome to our dedicated page for LiveWorld news (Ticker: $LVWD), a resource for investors and traders seeking the latest updates and insights on LiveWorld stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LiveWorld's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LiveWorld's position in the market.
LiveWorld (OTC Markets: LVWD) announced its financial results for Q1 2024, reporting total revenues of $2.6 million, a 6% decrease from the same period in 2023. Healthcare revenues accounted for $2.3 million. The company recorded a net loss of $498,000, compared to a net income of $134,000 in Q1 2023. Cash reserves decreased by $320,000 to $4.3 million. The company added pharma executives Helen Chang and Jennifer Sherak to its board and published a business report detailing its growth strategy. Management expects reduced losses and increased revenue in the upcoming quarters.